Intra-Cellular Therapies, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported revenue was USD 71.87 million compared to USD 22.21 million a year ago. Net loss was USD 53.51 million compared to USD 76.91 million a year ago. Basic loss per share from continuing operations was USD 0.57 compared to USD 0.95 a year ago.
For the nine months, revenue was USD 162.45 million compared to USD 58.13 million a year ago. Net loss was USD 212.23 million compared to USD 198.39 million a year ago. Basic loss per share from continuing operations was USD 2.26 compared to USD 2.44 a year ago.